c-Met / HGFR
Los inhibidores de c-Met/HGFR apuntan al Receptor del Factor de Crecimiento de Hepatocitos (c-Met), una tirosina quinasa involucrada en procesos celulares como el crecimiento, la motilidad y la morfogénesis. La señalización de c-Met está implicada en la progresión del cáncer, la metástasis y la resistencia a terapias. Inhibir c-Met puede interrumpir el crecimiento y la propagación del tumor, lo que hace que estos inhibidores sean valiosos en la investigación del cáncer. En CymitQuimica, ofrecemos inhibidores de c-Met/HGFR para apoyar su investigación en oncología, metástasis y terapias contra el cáncer dirigidas.
Se han encontrado 128 productos de "c-Met / HGFR"
Ordenar por
Pureza (%)
0
100
|
0
|
50
|
90
|
95
|
100
Bozitinib
CAS:<p>Bozitinib (PLB-1001) (PLB-1001) is a highly selective inhibitor of the c-MET kinase with blood-brain barrier permeability.</p>Fórmula:C20H15F3N8Pureza:99.16%Forma y color:SolidPeso molecular:424.38CSF1R-IN-2
CAS:<p>CSF1R-IN-2 is an oral-active SRC, MET and c-FMS inhibitor (IC50s: 0.12 nM, 0.14 nM and 0.76 nM for SRC, MET and c-FMS respectively).</p>Fórmula:C20H20FN7O2Pureza:99.29%Forma y color:SolidPeso molecular:409.42Onartuzumab
CAS:<p>Onartuzumab (MetMAb) is a humanized monoclonal antibody targeting c-MET, with antitumor effects by blocking HGF and signal transduction.</p>Pureza:97.3%Forma y color:LiquidPeso molecular:146.99 kDaPamufetinib
CAS:<p>Pamufetinib (TAS-115) is a potent inhibitor of VEGFR and hepatocyte growth factor receptor (c-Met/HGFR)-targeted kinase.</p>Fórmula:C27H23FN4O4SPureza:99.39%Forma y color:SolidPeso molecular:518.56JNJ-38877618
CAS:<p>JNJ-38877618 (OMO-1) is an effective and highly selective inhibitor of Met kinase (IC50s: 2 and 3 nM for wild type and mutant Met, respectively).</p>Fórmula:C20H12F2N6Pureza:98.84% - 99.74%Forma y color:SolidPeso molecular:374.35c-Met inhibitor 1
CAS:<p>c-Met inhibitor 1 is a c-Met receptor signaling pathway inhibitor, used for the treatment of cancer including glioblastoma, gastric, and pancreatic cancer.</p>Fórmula:C17H14N8SPureza:98.77%Forma y color:SolidPeso molecular:362.41Emibetuzumab
CAS:<p>Emibetuzumab: potent humanized MET antibody, antitumor, inhibits HGF/MET pathways, for advanced prostate cancer research.</p>Pureza:SDS-PAGE:96.2%;SEC-HPLC:98.8%Forma y color:LiquidPeso molecular:143.74 kDaRilotumumab
CAS:<p>Rilotumumab (AMG 102) is an HGF-targeting antibody, inhibits HGF/MET signaling, and is used for CRPC and gastric cancer research.</p>Pureza:SDS-PAGE:95% SEC-HPLC:97.51%Forma y color:LiquidPeso molecular:145.2 kDaPF-04217903 phenolsulfonate
CAS:<p>PF-04217903 phenolsulfonate is a potent ATP-competitive inhibitor of c-Met kinase (Ki of 4.8 nM for human c-Met).</p>Fórmula:C25H22N8O5SPureza:98%Forma y color:SolidPeso molecular:546.56Fosgonimeton acetate
<p>Fosgonimeton acetate is an agonist of hepatocyte growth factor (HGF).</p>Fórmula:C29H49N4O10PPureza:98.01%Forma y color:SolidPeso molecular:644.69Norleual
CAS:<p>Angiotensin IV analog, potent HGF/c-MET inhibitor (IC50=3 pM), halts MDCK cell growth and invasion, AT4 antagonist, impairs LTP, antiangiogenic.</p>Fórmula:C41H58N8O7Pureza:98%Forma y color:SolidPeso molecular:774.95Antitumor agent-111
<p>Antitumor Agent-111 (Compound 46), a c-Met kinase inhibitor (IC50 = 46 nM), exhibits both antitumor and antiproliferative effects.</p>Fórmula:C34H29ClF2N6O5Pureza:98%Forma y color:SolidPeso molecular:675.08c-Met-IN-18
<p>C-Met-IN-18, an ATP-competitive type-III inhibitor, targets both wild-type (WT) and D1228V mutant c-MET with IC50 values of 0.013 µM and 0.20 µM, respectively.</p>Fórmula:C21H15FN4O2Pureza:98%Forma y color:SolidPeso molecular:374.371D228
<p>1D228, a c-Met/TRK inhibitor with antitumor properties, suppresses cyclin D1 to precipitate G0/G1 arrest, thereby inhibiting proliferation and migration of</p>Pureza:98%Forma y color:Odour SolidNarnatumab
CAS:<p>Narnatumab (IMC-RON8) is a humanized antibody targeting the macrophage-stimulating receptor (RON) with antitumor activity, used in advanced malignant solid tumors research.</p>Pureza:>95%Forma y color:LiquidTelisotuzumab
CAS:<p>Telisotuzumab(ABT-700) is a humanized recombinant antibody targeting the therapeutic hepatocyte growth factor receptor (MET) with high affinity for c-Met.</p>Pureza:SDS-PAGE:96.4%;SEC-HPLC:98.5%Forma y color:LiquidPeso molecular:145.50 kDaC-Met inhibitor D9
CAS:<p>C-Met inhibitor D9 is a c-Met kinase inhibitor.</p>Fórmula:C17H15N3O2Pureza:97%Forma y color:SolidPeso molecular:293.32Umikibart
<p>Umikibart is a humanized IgG4κ antibody targeting HGF, with the corresponding isotype control being HumanIgG4(S228P) kappa, Isotype Control.</p>Forma y color:Odour LiquidPROTAC c-Met degrader-1
CAS:<p>PROTACc-Met degrader-1 (Compound Met-DD4) is an orally effective PROTAC degrader targeting c-Met with a DC50 of 6.21 nM. It inhibits the proliferation of c-Met-addicted MKN-45 cells with an IC50 of 4.37 nM and causes cell cycle arrest in the G0/G1 phase. In a xenograft mouse model using MKN-45 cells, PROTACc-Met degrader-1 demonstrates antitumor activity.</p>Fórmula:C45H41FN10O5Forma y color:SolidPeso molecular:820.87PROTAC c-Met degrader-3
<p>PROTACc-Met degrader-3 (Compound 22b) is a c-Met PROTAC degrader. It facilitates the ubiquitination and degradation of c-Met, with a DC50 of 0.59 nM in EBC-1 cells. PROTACc-Met degrader-3 is applicable in lung cancer research.</p>Fórmula:C51H54N10O7Forma y color:SolidPeso molecular:919.037c-Met-IN-23
<p>c-Met-IN-23 (Compound 12g) functions as a c-Met inhibitor with an IC50 of 0.052 μM against c-Met. It also inhibits the MDR1 and MRP1/2 pumps in cancerous HepG2 and BxPC3 cells. As such, c-Met-IN-23 serves as an anticancer agent.</p>Fórmula:C16H13N7OPeso molecular:319.11816SU 5616
CAS:<p>SU 5616 (WAY-608241) regulates abnormal cell proliferation and modulates tyrosine kinase signaling.</p>Fórmula:C13H8ClNOSPureza:98.84%Forma y color:SoildPeso molecular:261.73BMS-777607
CAS:<p>BMS-777607 is a Met-related inhibitor for c-Met, Axl, Ron and Tyro3.</p>Fórmula:C25H19ClF2N4O4Pureza:98.16% - 98.56%Forma y color:SolidPeso molecular:512.89c-Met-IN-19
<p>c-Met-IN-19 (Compound 21j) is a potent c-Met inhibitor with an IC50 of 1.99 nM and demonstrates cytotoxic effects on various cancer cell lines, including A549,</p>Fórmula:C34H37Cl2FN4O7SPureza:98%Forma y color:SolidPeso molecular:735.65LMTK3-IN-1
CAS:<p>Lmtk3-in-1 is a potent ATP-competitive lemur tyrosine kinase 3 (LMTK3) (Kd=2.5 μM) inhibitor that degrades LMTK3 through the ubiquitin proteasome pathway.</p>Fórmula:C18H11F3N4OPureza:99.89%Forma y color:SoildPeso molecular:356.3c-Met-IN-17
<p>c-Met-IN-17 is a potent inhibitor of c-Met kinase, demonstrating an IC50 of 0.031 μM, and is applicable in anticancer research. [1]</p>Fórmula:C21H15FN4O2Pureza:98%Forma y color:SolidPeso molecular:374.37SYN1143
CAS:<p>SYN1143 (AMG-1) strongly inhibits RON & c-Met with IC50s: 9 & 4 nmol/L.</p>Fórmula:C31H29FN4O5Pureza:99.69%Forma y color:SolidPeso molecular:556.58PF-04217903 methanesulfonate
CAS:<p>PF-04217903 methanesulfonate is a potent ATP-competitive inhibitor of c-Met kinase (Ki of 4.8 nM for human c-Met).</p>Fórmula:C20H20N8O4SPureza:98%Forma y color:SolidPeso molecular:468.49Merestinib dihydrochloride
CAS:<p>Merestinib dihydrochloride (LY2801653 dihydrochloride) is a kinase inhibitor with antitumor activity that inhibits MET and MKNK1/2.</p>Fórmula:C30H24Cl2F2N6O3Forma y color:SolidPeso molecular:625.45Afatinib Dimaleate
CAS:<p>Afatinib Dimaleate (BIBW 2992MA2) is an orally bioavailable anilino-quinazoline derivative and inhibitor of the EGFR family, with antineoplastic activity.</p>Fórmula:C32H33ClFN5O11Pureza:98.11% - 99.87%Forma y color:SolidPeso molecular:718.08c-Kit-IN-1
CAS:<p>c-Kit-IN-1 (DCC-2618) is an effective inhibitor of c-Met and c-Kit (IC50s<200 nM).</p>Fórmula:C26H21F2N5O3Pureza:98.72% - 98.73%Forma y color:SolidPeso molecular:489.47X-376
CAS:<p>X-376 (Ensartinib) is an orally available small molecule inhibitor of the receptor tyrosine kinase ALK with potential antineoplastic activity.</p>Fórmula:C25H25Cl2FN6O3Pureza:97.87%Forma y color:SolidPeso molecular:547.41BMS817378
CAS:<p>BMS817378 is a potent and selective inhibitor of MET(IC50 : 1.7 nM).</p>Fórmula:C24H18ClF2N4O7PPureza:>99.99%Forma y color:SolidPeso molecular:578.85Ensartinib hydrochloride
CAS:<p>Ensartinib hydrochloride (X-396 dihydrochloride) is a potent new-generation ALK inhibitor with high activity against CNS metastases and a broad range of known</p>Fórmula:C26H29Cl4FN6O3Pureza:98.73%Forma y color:SolidPeso molecular:634.36Glumetinib
CAS:<p>Glumetinib (SCC244) (SCC 244) is a novel potent and selective inhibitor of c-Met kinase (IC50: 0.42 nM).</p>Fórmula:C21H17N9O2SPureza:99.79%Forma y color:SolidPeso molecular:459.48Hepln-13
CAS:<p>Hepln-13 is a hepsin inhibitor that acts by hindering prostate cancer bone metastasis.</p>Fórmula:C17H13BrN2Pureza:97.67%Forma y color:SolidPeso molecular:325.2Altiratinib
CAS:<p>Altiratinib (DCC-2701)(DCC-2701) is a novel c-MET/TIE-2/VEGFR inhibitor; effectively reduce tumor burden in vivo and block c-MET pTyr(1349)-mediated signaling,</p>Fórmula:C26H21F3N4O4Pureza:99.67% - 99.75%Forma y color:SolidPeso molecular:510.46NVP-BVU972
CAS:<p>NVP-BVU972 is a selective and potent Met inhibitor with IC50 of 14 nM.</p>Fórmula:C20H16N6Pureza:97.24% - >99.99%Forma y color:SolidPeso molecular:340.38BMS 777607
CAS:<p>BMS 777607 (BMS 817378) is a Met-related inhibitor for c-Met/Axl/Ron/Tyro3. BMS-777607 has been investigated for the basic science of Malignant Solid Tumour.</p>Fórmula:C25H19ClF2N4O4Pureza:98.30% - >99.99%Forma y color:SolidPeso molecular:512.89MK-8033
CAS:<p>MK-8033 is a new and selective dual ATP competitive c-Met/Ron inhibitor (IC50: 1 nM Wt c-Met).</p>Fórmula:C25H21N5O3SPureza:97.16%Forma y color:SolidPeso molecular:471.53Golvatinib
CAS:<p>Golvatinib (E-7050) is an orally bioavailable dual kinase inhibitor of c-Met (hepatocyte growth factor receptor) and VEGFR-2 (vascular endothelial growth factor</p>Fórmula:C33H37F2N7O4Pureza:98.24% - ≥95%Forma y color:SolidPeso molecular:633.69AMG-337
CAS:<p>AMG-337 is an effective and highly specific ATP-competitive MET kinase inhibitor. In enzymatic assays, AMG-337 inhibits MET kinase activity (IC50: < 5 nM).</p>Fórmula:C23H22FN7O3Pureza:99.26% - 99.9%Forma y color:SolidPeso molecular:463.46Capmatinib 2HCl.H2O
CAS:<p>Capmatinib 2HCl.H2O (NVP-INC280 2HCl.H2O) is an orally bioavailable inhibitor of the proto-oncogene c-Met (HGFR)with potential antineoplastic activity.</p>Fórmula:C23H21Cl2FN6O2Pureza:99.77%Forma y color:SolidPeso molecular:503.36Foretinib
CAS:<p>Foretinib (GSK1363089) is a broad-spectrum tyrosine kinase inhibitor with IC50s of 0.4 nM and 0.9 nM for Met and KDR.</p>Fórmula:C34H34F2N4O6Pureza:98.07% - 99.68%Forma y color:SolidPeso molecular:632.65Ningetinib
CAS:<p>Ningetinib (CT-053) (CT053PTSA) is an orally bioavailable tyrosine kinase inhibitor with IC50s of <1.0, 1.9 and 6.7 nM for Axl, VEGFR2, and c-Met, respectively.</p>Fórmula:C31H29FN4O5Pureza:99.95% - 99.98%Forma y color:SolidPeso molecular:556.58Crizotinib hydrochloride
CAS:<p>Crizotinib hydrochloride (PF-02341066 hydrochloride) is a novel inhibitor of anaplastic lymphoma kinase and c-Met(IC50s of 20 and 8 nM)</p>Fórmula:C21H23Cl3FN5OPureza:98.73% - 98.87%Forma y color:SolidPeso molecular:486.8Tivantinib
CAS:<p>Tivantinib (ARQ 197) is an orally bioavailable small molecule inhibitor of c-Met with potential antineoplastic activity.</p>Fórmula:C23H19N3O2Pureza:98% - 99.41%Forma y color:SolidPeso molecular:369.42NPS-1034
CAS:<p>NPS-1034 is a dual Met/Axl inhibitor with IC50 of 48 nM and 10.3 nM, respectively.</p>Fórmula:C31H23F2N5O3Pureza:98.48%Forma y color:SolidPeso molecular:551.54CEP-40783
CAS:<p>CEP-40783 (RXDX-106) is an effective, specific and orally active AXL/c-Met inhibitor (IC50: 7/12 nM). It also inhibits MER and TYRO3 (IC50: 29/19 nM).</p>Fórmula:C31H26F2N4O6Pureza:99.76% - 99.84%Forma y color:SolidPeso molecular:588.56Ningetinib Tosylate
CAS:<p>Ningetinib Tosylate is an orally bioavailable tyrosine kinase inhibitor with IC50s of <1.0, 1.9 and 6.7 nM for Axl, VEGFR2, and c-Met, respectively.</p>Fórmula:C38H37FN4O8SPureza:99.93%Forma y color:SolidPeso molecular:728.79Crizotinib
CAS:<p>Crizotinib (PF-02341066) is an ATP-competitive small-molecule tyrosine kinases inhibitor of c-MET (IC50: 8 nM) and ALK (IC50: 20 nM) receptor.</p>Fórmula:C21H22Cl2FN5OPureza:99% - 99.87%Forma y color:SolidPeso molecular:450.34AMG-208
CAS:<p>AMG-208 is a highly selective c-Met inhibitor with IC50 of 9 nM. Phase 1.</p>Fórmula:C22H17N5O2Pureza:98.56%Forma y color:SolidPeso molecular:383.4S49076
CAS:<p>S49076 is a novel, potent inhibitor of MET, AXL/MER, and FGFR1/2/3, blocking cellular phosphorylation of MET, AXL, and FGFRs.</p>Fórmula:C22H22N4O4SPureza:95.35% - 97.4%Forma y color:SolidPeso molecular:438.5DS-1205
CAS:<p>DS-1205: AXL kinase inhibitor (IC50=1.3 nM), also targets MER, MET, TRKA (IC50s: 63, 104, 407 nM), hinders cell migration and tumor growth.</p>Fórmula:C41H42FN5O7Pureza:99.75%Forma y color:SolidPeso molecular:735.8Capmatinib 2HCl
CAS:<p>Capmatinib 2HCl (INC-280 2HCl), a c-MET inhibitor, is potent (IC50 = 0.13 nM), highly specific, and induces apoptosis in tumor cells.</p>Fórmula:C23H19Cl2FN6OPureza:98.80%Forma y color:SolidPeso molecular:485.34SGX-523
CAS:<p>SGX-523 is a selective Met inhibitor (IC50: 4 nM), no inhibitory to Abl, BRAFV599E, p38α, and c-Raf.</p>Fórmula:C18H13N7SPureza:99% - >99.99%Forma y color:SolidPeso molecular:359.41BMS-794833
CAS:<p>BMS-794833 is a potent ATP competitive inhibitor of Met/VEGFR2; a prodrug of BMS-817378.</p>Fórmula:C23H15ClF2N4O3Pureza:98% - 99.69%Forma y color:SolidPeso molecular:468.84XL092
CAS:<p>XL092 (JUN04542) is an Axl Mer cMet KDR inhibitor for the treatment of Axl and Mer receptor tyrosine kinase- dependent disorders.</p>Fórmula:C29H25FN4O5Pureza:98.60%Forma y color:SolidPeso molecular:528.53SCR-1481B1
CAS:<p>SCR-1481B1 (c-Met inhibitor 2) has activity against cancers dependent on Met activation and also has activity against cancers as a VEGFR inhibitor</p>Fórmula:C32H40ClF2N6O13PPureza:98.07%Forma y color:SolidPeso molecular:821.12Amuvatinib
CAS:<p>Amuvatinib (MP470) is an orally bioavailable synthetic carbothioamide with potential antineoplastic activity.</p>Fórmula:C23H21N5O3SPureza:99.38% - >99.99%Forma y color:SolidPeso molecular:447.51PHA-665752
CAS:<p>PHA-665752 is an effective, specific and ATP-competitive c-Met inhibitor (IC50: 9 nM), >50-fold selectivity for c-Met than STKs or RTKs.</p>Fórmula:C32H34Cl2N4O4SPureza:97.05% - 98.82%Forma y color:SolidPeso molecular:641.61Capmatinib
CAS:<p>Capmatinib (INCB28060) is an orally bioavailable inhibitor of the proto-oncogene c-Met (HGFR)with potential antineoplastic activity.</p>Fórmula:C23H17FN6OPureza:99.24%Forma y color:SolidPeso molecular:412.42PF-04217903
CAS:<p>MET Tyrosine Kinase Inhibitor PF-04217903 is an orally bioavailabe, small-molecule tyrosine kinase inhibitor with potential antineoplastic activity.</p>Fórmula:C19H16N8OPureza:98.41% - 98.55%Forma y color:SolidPeso molecular:372.38SAR125884 hydrochlorid (1116743-46-4(free base))
CAS:<p>SAR125844 is a potent and selective MET kinase inhibitor with a favorable preclinical toxicity profile,(IC50=4.2 nM).</p>Fórmula:C25H23FN8O2S2·HClPureza:97.95%Forma y color:SolidPeso molecular:587JNJ-38877605
CAS:<p>JNJ-38877605 is an ATP-competitive c-Met inhibitor (IC50: 4 nM), 600-fold selective for c-Met than 200 other tyrosine and serine-threonine kinases.</p>Fórmula:C19H13F2N7Pureza:97.04% - 98.27%Forma y color:SolidPeso molecular:377.35Merestinib
CAS:<p>Merestinib (LY2801653) is an orally available, small molecule inhibitor of the proto-oncogene c-Met (Ki: 2 nM) with potential antineoplastic activity.</p>Fórmula:C30H22F2N6O3Pureza:95% - 99.71%Forma y color:SolidPeso molecular:552.53MGCD-265 analog
CAS:<p>Glesatinib, an oral tyrosine kinase inhibitor, targets c-Met and VEGFR2 with IC50s of 29 nM and 10 nM, may treat cancer.</p>Fórmula:C26H20FN5O2S2Pureza:98.06% - 98.68%Forma y color:SolidPeso molecular:517.6Savolitinib
CAS:<p>Savolitinib (Volitinib) (AZD-6094) is an effective, selective, and orally bioavailable c-Met inhibitor (IC50s: 5 nM/3 nM for c-Met/p-Met).</p>Fórmula:C17H15N9Pureza:98.12%Forma y color:SolidPeso molecular:345.36Capmatinib xHCl
CAS:<p>Capmatinib xHCl (INCB28060) is a potent, orally active, selective, and ATP competitive c-Met kinase inhibitor, potently blocking in vitro kinase activity (IC50</p>Fórmula:C23H18ClFN6OPureza:98.62% - 99.81%Forma y color:SolidPeso molecular:448.89SRI 31215 TFA
CAS:<p>SRI 31215 TFA acts as a triplex inhibitor of matriptase, hepsin and HGFA and mimics the activity of HAI-1/2, endogenous inhibitors of HGF activation.</p>Fórmula:C27H34F3N5O3Pureza:98.25% - 99.97%Forma y color:SolidPeso molecular:533.6Cabozantinib
CAS:<p>Cabozantinib (XL184) is a multi-targeted tyrosine kinase receptor inhibitor that inhibits VEGFR2, c-Met, Kit, Axl, and Flt3 (IC50=0.035/1.3/4.6/7/11.3 nM).</p>Fórmula:C28H24FN3O5Pureza:99.68% - 99.88%Forma y color:SolidPeso molecular:501.51(Z)-Semaxinib
CAS:<p>(Z)-Semaxinib (SU5416) is a potent and selective VEGFR(Flk-1/KDR) inhibitor (IC50: 1.23 μM), 20-fold more selective for VEGFR over PDGFRβ, no inhibition for</p>Fórmula:C15H14N2OPureza:98.82% - ≥95%Forma y color:SolidPeso molecular:238.28Cabozantinib hydrochloride
CAS:<p>Cabozantinib hydrochloride (XL184) is a potent pan-tyrosine kinases inhibitor that inhibits VEGFR2, c-Met, Kit, Axl, and Flt4 (IC50s: 0.035, 1.3, 4.6, 7 and 6</p>Fórmula:C28H25ClFN3O5Pureza:99.97%Forma y color:SolidPeso molecular:537.96BAY-474
CAS:<p>BAY-474 is an inhibitor of tyrosine-protein kinase c-Met. It acts as an epigenetics probe</p>Fórmula:C17H15N5Pureza:98.98%Forma y color:SolidPeso molecular:289.33Afatinib
CAS:<p>Afatinib (BIBW 2992) is an irreversible and orally EGFR family inhibitor that inhibits EGFR and HER2. Afatinib has antitumor activity. Cost effective and quality assured.</p>Fórmula:C24H25ClFN5O3Pureza:98.56% - 99.9%Forma y color:Off-White SolidPeso molecular:485.94Amivantamab
CAS:<p>Amivantamab (JNJ-61186372) is an antibody that recognizes EGFR and MET and has anticancer and antitumor activities.</p>Pureza:97.24% (SEC-HPLC) - 99.74%Forma y color:LiquidPeso molecular:145.88 kDaFiclatuzumab
CAS:<p>Ficlatuzumab is a humanized anti-HGF mAb that inhibits c-Met signaling for squamous cell carcinoma treatment.</p>Pureza:95%Forma y color:LiquidDavutamig
CAS:<p>Davutamig (REGN-5093) is a humanized IgG4-kappa, anti-MET monoclonal antibody that binds to two distinct, nonoverlapping epitopes on the MET receptor.</p>Pureza:98%Forma y color:LiquidBafisontamab
CAS:<p>Bafisontamab (EMB-01) is a bispecific antibody that targets EGFR and cMET, displaying antitumor activity [1].</p>Forma y color:LiquidMAPK-IN-2
<p>MAPK-IN-2 (compound 3h) is an efficacious MAPK inhibitor with antineoplastic properties that significantly hinders proliferation across various cancer cell</p>Fórmula:C20H11Cl2N3OPureza:98%Forma y color:SolidPeso molecular:380.23SU11274
CAS:<p>SU11274 (Met Kinase Inhibitor)(IC50=10 nM) is a specific Met inhibitor. It shows no significant effects on PGDFRβ, EGFR or Tie2.</p>Fórmula:C28H30ClN5O4SPureza:98.62% - 99.53%Forma y color:Orange PowderPeso molecular:568.09AMG-458
CAS:<p>AMG-458 is a potent c-Met inhibitor with Ki of 1.2 nM, ~350-fold selectivity for c-Met than VEGFR2 in cells.</p>Fórmula:C30H29N5O5Pureza:99.91% - 99.98%Forma y color:SolidPeso molecular:539.58Glesatinib
CAS:<p>Glesatinib is an orally active and potent dual inhibitor of MET/SMO.</p>Fórmula:C31H27F2N5O3S2Pureza:98%Forma y color:SolidPeso molecular:619.7Dalmelitinib
CAS:<p>Dalmelitinib: oral c-Met kinase inhibitor, IC50 2.9 nM, disrupts MET, AKT, ERK in cancer cells, for NSCLC research.</p>Fórmula:C22H16FN7O2SForma y color:SolidPeso molecular:461.47c-Met-IN-16
CAS:<p>c-Met-IN-16 is a c-Met inhibitor that can be used for cancer research .</p>Fórmula:C21H17F2N9OForma y color:SolidPeso molecular:449.42ABN401
CAS:<p>ABN401: potent c-MET inhibitor (IC50: 10 nM), cytotoxic to MET-dependent cancers, blocks tumor c-MET phosphorylation, for cancer research.</p>Fórmula:C29H34N12OForma y color:SolidPeso molecular:566.66AC-386
CAS:<p>AC-386, a potent c-Met inhibitor (IC50 7.42 nM), inhibits cancer cell growth and aids anti-cancer resistance study.</p>Fórmula:C35H34FN5O6Forma y color:SolidPeso molecular:639.67Tyrosine kinase-IN-4
CAS:<p>Tyrosine kinase-IN-4 (EXAMPLE 107) is a protein tyrosine kinase inhibitor [1].</p>Fórmula:C23H21N3O3Forma y color:SolidPeso molecular:387.43LCRF-0004
CAS:<p>LCRF-0004 inhibits RON kinase, key in KRAS-driven pancreatic cancer, reducing cell migration and enhancing chemo sensitivity.</p>Fórmula:C28H18F4N6O2SForma y color:SolidPeso molecular:578.54c-Met-IN-13
CAS:<p>c-Met-IN-13: potent c-Met inhibitor (IC50 2.43 nM), exhibits anti-proliferative, cytotoxic effects; potential cancer therapy.</p>Fórmula:C30H28F2N2O6Forma y color:SolidPeso molecular:550.55SAR125844
CAS:<p>SAR125844, a potent and highly selective inhibitor of the MET receptor tyrosine kinase (RTK), for intravenous administration. (IC50 value of 4.2 nmol/L)</p>Fórmula:C25H23FN8O2S2Pureza:98.73%Forma y color:SolidPeso molecular:550.63c-Met-IN-11
CAS:<p>c-Met-IN-11 is a potent inhibitor of c-MET (IC50: 41.4 nM) and VEGFR-2 (IC50: 71.1 nM).</p>Fórmula:C30H20F2N4O3Forma y color:SolidPeso molecular:522.5Glesatinib hydrochloride
CAS:<p>Glesatinib hydrochloride is an orally active and potent dual inhibitor of MET/SMO.</p>Fórmula:C31H28ClF2N5O3S2Pureza:98%Forma y color:SolidPeso molecular:656.16Axl-IN-8
CAS:<p>Axl-IN-8 (NO.1) is a potent inhibitor of AXL (IC50<1 nM) and also inhibits c-MET (IC50: 1-10 nM). : 120.3 nM).</p>Fórmula:C31H29FN6O3Forma y color:SolidPeso molecular:552.6T-1840383
CAS:<p>T-1840383 blocks VEGFR-2 and c-Met phosphorylation in endothelial and cancer cells.</p>Fórmula:C30H25ClFN5O4Forma y color:SolidPeso molecular:574MK-8033 hydrochloride
CAS:<p>MK-8033 hydrochloride is an oral ATP-competitive c-Met/Ron inhibitor (IC50: c-Met 1nM, Ron 7nM), used for various cancers including NSCLC.</p>Fórmula:C25H22ClN5O3SForma y color:SolidPeso molecular:507.99Mifanertinib dimaleate
CAS:<p>Mifanertinib dimaleate is a potent tyrosine kinase inhibitor with antineoplastic activity .</p>Fórmula:C29H27ClF3N5O10Forma y color:SolidPeso molecular:698c-Met-IN-12
CAS:<p>c-Met-IN-12: potent c-Met/AXL/Mer/TYRO3 inhibitor, IC50=10.6 nM, oral, anti-tumor, scaffold for selectivity enhancement.</p>Fórmula:C34H29FN4O4Forma y color:SolidPeso molecular:576.62Boditrectinib
CAS:<p>Boditrectinib: potent TKI, anti-cancer, researches cancer, inflammation, neurodegeneration, infections.</p>Fórmula:C23H24F2N6OForma y color:SolidPeso molecular:438.47Mifanertinib
CAS:<p>Mifanertinib is a potent tyrosine kinase inhibitor with antineoplastic activity .</p>Fórmula:C21H19ClF3N5O2Forma y color:SolidPeso molecular:465.86(R)-Afatinib
CAS:<p>(R)-Afatinib: oral ErbB inhibitor (EGFR/HER2), IC50 ≤14 nM. For ESCC, NSCLC, gastric cancer research.</p>Fórmula:C24H25ClFN5O3Forma y color:SolidPeso molecular:485.94Vabametkib
CAS:<p>Vabametkib: potent HGFR inhibitor, IC50 = 7 nM, halts Hs746T cell growth, used in cancer therapy.</p>Fórmula:C29H34N12OForma y color:SolidPeso molecular:566.66SOMG-833 HCl
CAS:<p>SOMG-833 HCl is a selective inhibitor of c-MET. It acts by blocking c-MET dependent neoplastic effects and exerting antitumor activity.</p>Fórmula:C22H22F3N5O2Pureza:98%Forma y color:SolidPeso molecular:445.44met-kinase-in-2
CAS:<p>MET kinase-IN-2, a selective and potent MET kinase inhibitor, demonstrates oral bioavailability and exhibits an IC50 value of 7.4 nM.</p>Fórmula:C33H27FN4O4Forma y color:SolidPeso molecular:562.59Entacapone acid
CAS:<p>Entacapone acid (AG 1290) is a selective and reversible inhibitor of catechol-O-methyltransferase(COMT).</p>Fórmula:C10H6N2O6Pureza:98.86%Forma y color:SolidPeso molecular:250.16SOMCL-863
CAS:<p>SOMCL-863 is a selective and orally bioavailable c-Met inhibitor. It shows antitumor activity both in vitro and in vivo.</p>Fórmula:C23H24F3N5O3Pureza:98%Forma y color:SolidPeso molecular:475.46BPI-9016M
CAS:<p>BPI-9016M, an oral c-Met/AXL inhibitor, curbs growth and spread of lung cancer.</p>Fórmula:C25H18F2N4O3Forma y color:SolidPeso molecular:460.43Terevalefim
CAS:<p>Terevalefim (ANG-3777) is an hepatocyte growth factor (HGF) mimetic. Terevalefim selectively activates the c-Met receptor.</p>Fórmula:C9H8N2SPureza:99.8%Forma y color:SolidPeso molecular:176.24c-met-IN-1
CAS:<p>c-met-IN-1 is a potent and selective c-Met inhibitor (IC50: 1.1 nM) with antitumor activity.</p>Fórmula:C35H37FN6O5Pureza:98%Forma y color:SolidPeso molecular:640.7OSI-296
CAS:<p>OSI-296: potent cMET/RON inhibitor (IC50: 42/200 nM), effective in tumor models, tolerable, oral, reduces bone tumor growth.</p>Fórmula:C21H19Cl2FN4O3Pureza:98%Forma y color:SolidPeso molecular:465.3MET kinase-IN-3
CAS:<p>MET kinase-IN-3 is a potent, orally active MET inhibitor (IC50: 9.8 nM) that exhibits good broad-spectrum anti-proliferative effects on cancer cells.</p>Fórmula:C25H16ClF2N5O2Forma y color:SolidPeso molecular:491.88Adrixetinib
CAS:<p>Adrixetinib is an inhibitor of protein tyrosine kinase with antineoplastic activity .</p>Fórmula:C25H24F3N5O5Forma y color:SolidPeso molecular:531.48Emzeltrectinib
CAS:<p>Emzeltrectinib is a potent tyrosine kinase inhibitor with antineoplastic activity .</p>Fórmula:C17H15F3N6OForma y color:SolidPeso molecular:376.34Resencatinib
CAS:<p>Resencatinib is a potent tyrosine kinase inhibitor with antineoplastic activity .</p>Fórmula:C30H29N7O3Forma y color:SolidPeso molecular:535.6Tyrosine kinase-IN-6
CAS:<p>Tyrosine kinase-IN-6 is a potent inhibitor of RON splice variants, demonstrating significant anticancer and antineoplastic effects [1].</p>Fórmula:C37H31F2N5O5SPureza:98%Forma y color:SolidPeso molecular:695.73MK-2461
CAS:<p>MK-2461 is a novel inhibitor that targets multiple proteins and competitively binds to ATP sites, specifically inhibiting the activated c-Met protein with an</p>Fórmula:C24H25N5O5SPureza:95.41% - 99.53%Forma y color:SolidPeso molecular:495.55Zongertinib
CAS:<p>Zongertinib is a human HER2-selective tyrosine kinase inhibitor, a novel TK that is highly selective for covalent binding to the HER2 tyrosine kinase domain (</p>Fórmula:C29H29N9O2Pureza:98.24%Forma y color:SolidPeso molecular:535.6EGFR-IN-8
CAS:<p>EGFR-IN-8, a dual inhibitor targeting both EGFR and c-Met, shows potential as a promising candidate for further development in treating EGFR TKI-resistant NSCLC</p>Fórmula:C32H23ClF3N7O4Pureza:99.51%Forma y color:SolidPeso molecular:662.02c-Met-IN-2
CAS:<p>c-Met-IN-2 is a selective and orally available c-Met inhibitor (IC50: 0.6 nM) with antitumor activity.</p>Fórmula:C24H21FN10OPureza:98%Forma y color:SolidPeso molecular:484.49SJF 8240
CAS:<p>c-MET degrader with foretinib linked to VHL ligand; reduces c-MET in 6h, hampers AKT, halts GTL16 cells (IC50=66.7nM), acts on exon-14-less c-MET.</p>Fórmula:C58H65F2N7O11SForma y color:SolidPeso molecular:1106.25BMS-748730
CAS:<p>BMS-748730, also known as 4′-Hydroxy Dasatinib, is a Dasatinib metabolite.</p>Fórmula:C22H26ClN7O3SForma y color:SolidPeso molecular:504.01D6808
<p>D6808: selective c-Met inhibitor, IC50=2.9 nM, induces apoptosis and cell cycle arrest, for NSCLC/gastric cancer research.</p>Fórmula:C30H25F3N6O2Forma y color:SolidPeso molecular:558.55c-Met-IN-26
CAS:<p>c-Met-IN-26 (compound 1-170) is an effective inhibitor of c-Met, exhibiting an IC50 of 1.6 nM.</p>Fórmula:C24H19F2N9Forma y color:SolidPeso molecular:471.46TAM&Met-IN-1
CAS:<p>TAM&Met-IN-1 inhibits AXL, MER, TYRO3 with IC50s 6.1, 13.2, 21.6 nM, respectively, for cancer research.</p>Fórmula:C29H27F2N7O5Forma y color:SolidPeso molecular:591.57Zurletrectinib
CAS:<p>Zurletrectinib is a tyrosine kinase inhibitor with potential as an antineoplastic agent.</p>Fórmula:C19H19F2N7O2Forma y color:SolidPeso molecular:415.4KRC-00715
CAS:<p>KRC-00715 is an orally effective inhibitor of c-Met, exhibiting high selectivity with an IC50 of 9.0 nM. This compound specifically inhibits the growth of gastric cancer cell lines with high c-Met expression by inducing G1/S phase block, and reduces the activity of downstream signals, including Akt, Erk, and c-Met itself. In the gastric cancer cell line Hs746T, KRC-00715 demonstrates cytotoxicity with an IC50 of 39 nM and selectively inhibits the proliferation of cell lines that overexpress c-Met. Additionally, KRC-00715 decreases tumor size in Hs746T xenograft mouse models.</p>Fórmula:C25H25F3N8O3Forma y color:SolidPeso molecular:542.51Tyrosine kinase inhibitor
CAS:<p>Tyrosine kinase inhibitor is a tyrosine kinase inhibitor used in combination with fragmenting aromatic nitrogen compounds as antiproliferative agents.</p>Fórmula:C31H31FN6O5Pureza:98%Forma y color:SolidPeso molecular:586.61Canlitinib
CAS:<p>Canlitinib, a tyrosine kinase inhibitor, holds potential for cancer research.</p>Fórmula:C33H31F2N3O7Pureza:98%Forma y color:SolidPeso molecular:619.61
